Document Detail

Folic acid supplementation and cancer risk: A meta-analysis of randomized controlled trials.
MedLine Citation:
PMID:  23338728     Owner:  NLM     Status:  Publisher    
There are growing data and a continuing controversy over the effect of folic acid supplementation on cancer risk. We conducted a meta-analysis based on up-to-date published relevant randomized trials to further examine this issue. Relative risk (RR) was used to measure the effect of folic acid supplementation on risk of cancer using a random-effects model. Overall, folic acid supplementation had no significant effect on total cancer incidence (13 trials, n=49,406, RR=1.05; 95%CI: 0.99-1.11, P=0.13), colorectal cancer(7 trials, n=33,824, 1.01; 0.82-1.23, P=0.95), other gastrointestinal cancer (2 trials, n=20,228, 1.00; 0.75-1.33, P=0.99), prostate cancer(5 trials, n=27,065, 1.17; 0.84-1.62, P=0.35), other genitourinary cancer (2 trials, n=20,228, 0.97; 0.75-1.27, P=0.84), lung cancer (5 trials, n=31,864, 1.00; 0.84-1.21, P=0.97), breast cancer(4 trials, n=19,800, 0.82; 0.63-1.07, P=0.15), hematological malignancy (3 trials, n=25,670, 0.87; 0.64-1.17, P=0.35), and total cancer mortality (6 trials, n=31,930, 1.02; 0.90-1.15, P=0.81). However, a significantly reduced risk was observed for melanoma (3 trials, n=19,128, 0.47; 0.23-0.94, P=0.03). Furthermore, higher total cancer incidence risk was observed among those trials with a higher percent use of lipid-lowering drugs (<60%, 1.10; 1.00-1.20, P=0.04), or with lower percent baseline hypertension (≤70%, 1.08; 1.00-1.16, P=0.057).Consistently, meta-regression analyses suggested that the similar trend between percent use of lipid-lowering drugs (P=0.084) or percent baseline hypertension (P=0.056) and log-RR for total cancer incidence was associated with folic acid supplementation. Our findings indicate that folic acid supplementation has no significant effect on total cancer incidence, colorectal cancer, prostate cancer, lung cancer, breast cancer, or hematological malignancy, but reduces the risk of melanoma. © 2013 Wiley Periodicals, Inc.
Xianhui Qin; Yimin Cui; Lin Shen; Ningling Sun; Yan Zhang; Jianping Li; Xin Xu; Binyan Wang; Xiping Xu; Yong Huo; Xiaobin Wang
Related Documents :
23130878 - Increased registration of hypertension and cancer diagnoses after the introduction of a...
24638118 - Validation of disability status, a claims-based measure of functional status for cancer...
24445948 - The effect of testosterone replacement therapy on prostate cancer: a systematic review ...
24197978 - Glutathione s-transferase m1 polymorphism and colorectal cancer risk in chinese populat...
11204658 - Second-line therapy in colorectal cancer.
23645148 - Decreased expression of long noncoding rna ac096655.1-002 in gastric cancer and its cli...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-22
Journal Detail:
Title:  International journal of cancer. Journal international du cancer     Volume:  -     ISSN:  1097-0215     ISO Abbreviation:  Int. J. Cancer     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-22     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0042124     Medline TA:  Int J Cancer     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2013 UICC.
Division of Nephrology, Nanfang Hospital, Southern Medical University, Guangzhou, China; Institute of Biomedicine, Anhui Medical University, Hefei, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The zinc-binding fragment of HypA from Helicobacter pylori: a tempting site also for nickel ions.
Next Document:  Lessons Learned From Fatal Progressive Multifocal Leukoencephalopathy in a Patient With Multiple Scl...